NCT04875299 Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients Status UNKNOWN Phase N/A
NCT04867148 The Prediction and Prevention of Disease by Using Big Data in Motion Analysis Status UNKNOWN Phase NA
NCT04840485 Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis Status COMPLETED Phase PHASE2/PHASE3
NCT04820725 The Effects of Postural Changes on Plantar Pressure in Patients With Ankylosing Spondylitis Status UNKNOWN Phase NA
NCT04795141 ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis Status TERMINATED Phase PHASE2
NCT04772976 Relationship Between Diet, Oxidative Stress and Inflammation in Ankylosing Spondylitis Status COMPLETED Phase N/A
NCT04751396 Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors Status RECRUITING Phase N/A
NCT04749537 Work Productivity and Social Activities In Patients With Ankylosing Spondylitis Status COMPLETED Phase N/A
NCT04713813 Effectiveness of Hippotherapy Simulator in Ankylosing Spondylitis Status COMPLETED Phase NA
NCT04655612 Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases Status COMPLETED Phase N/A
NCT04582084 Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis Status COMPLETED Phase N/A
NCT04507763 Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis Status COMPLETED Phase N/A
NCT04507659 Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis Status COMPLETED Phase PHASE2
NCT04483700 Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy Status WITHDRAWN Phase PHASE3
NCT04483687 Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy Status WITHDRAWN Phase PHASE3